Registry-listed formulations

Ibandronate Sodium · mesh:M000629520

Each study is counted once in the molecule profile. Registry products remain separate. Naming an ingredient does not establish that products are interchangeable or what participants received.

1 source entries across 1 studies. This list may not include all unresolved or historical entries.

  • ibandronateRegistry intervention

    Linked study entry; product equivalence not established

    View study and source

Success Metrics

Clinical Success Rate
100.0%

Based on 3 completed trials

Completion Rate
100%(3/3)
Active Trials
0(0%)
Results Posted
33%(1 trials)

Phase Distribution

Phase 3
4
67%
Phase 1
1
17%

Phase Distribution

1

Early Stage

0

Mid Stage

4

Late Stage

Phase Distribution5 total trials
Phase 1Safety & dosage
1(20.0%)
Phase 3Large-scale testing
4(80.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

60.0%

3 of 5 finished

Non-Completion Rate

40.0%

2 ended early

Currently Active

0

trials recruiting

Total Trials

6

all time

Status Distribution
Completed(3)
Terminated(2)
Other(1)

Detailed Status

Completed3
Withdrawn2
unknown1

Development Timeline

Analytics

Development Status

Total Trials
6
Active
0
Success Rate
100.0%
Most Advanced
Phase 3

Trials by Phase

Phase 11 (20.0%)
Phase 34 (80.0%)

Trials by Status

completed350%
unknown117%
withdrawn233%

Recent Activity

0 active trials
Showing 5 of 6
completedphase_3

S0307 Phase III Trial of Bisphosphonates as Adjuvant Therapy for Primary Breast Cancer.

NCT00127205
withdrawnphase_3

S0308 Zoledronate or Ibandronate in Preventing Bone Problems in Women With Stage IV Breast Cancer That Has Spread to the Bone

NCT00301886
completedphase_3

Single-Dose Local Radiation Therapy Compared With Ibandronate in Treating Patients With Localized Metastatic Bone Pain

NCT00082927
withdrawn

S0307A, Long-Term Bone Quality in Women With Breast Cancer Enrolled on Clinical Trial SWOG-S0307

NCT00873808
unknownphase_3

Ibandronate or Zoledronate in Treating Patients With Newly Diagnosed Bone Metastases From Breast Cancer

NCT00326820
View all 6 trials

Clinical Trials (6)

Showing 6 of 6 trials
NCT00127205Phase 3

S0307 Phase III Trial of Bisphosphonates as Adjuvant Therapy for Primary Breast Cancer.

Completed
NCT00301886Phase 3

S0308 Zoledronate or Ibandronate in Preventing Bone Problems in Women With Stage IV Breast Cancer That Has Spread to the Bone

Withdrawn
NCT00082927Phase 3

Single-Dose Local Radiation Therapy Compared With Ibandronate in Treating Patients With Localized Metastatic Bone Pain

Completed
NCT00873808

S0307A, Long-Term Bone Quality in Women With Breast Cancer Enrolled on Clinical Trial SWOG-S0307

Withdrawn
NCT00326820Phase 3

Ibandronate or Zoledronate in Treating Patients With Newly Diagnosed Bone Metastases From Breast Cancer

Unknown
NCT01627886Phase 1

Bioequivalence Study of Ibandronate Sodium Tablets 150 mg Under Fasting Condition

Completed

All 6 trials loaded

Drug Details

Intervention Type
Drug
Molecule Type
Small molecule
Total Trials
6

External References

ChEMBL
CHEMBL3989569